Long-term laryngeal allograft survival using low-dose everolimus

Otolaryngology - Head and Neck Surgery

Volumn 142, Issue 1, 2010, Pages 72-78

  Lott, David G ^a   Dan, Olivia ^a   Lu, Lina ^a   Strome, Marshall ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b New York Head & Neck Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL FUNCTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE SEVERITY; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNE RESPONSE; LARYNGEAL ALLOGRAFT; LARYNX; MALE; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE;

ANIMALS; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE AGENTS; LARYNX; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; SIROLIMUS; TIME FACTORS;

EID: 72349098204     PISSN: 01945998     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otohns.2009.10.019     Document Type: Article

References (20)

1. Genden E.M., and Urken M.L. Laryngeal and tracheal transplantation: ethical limitations. Mt Sinai J Med 70 (2003) 163-165
2. Strome M., Stein J., Esclamado R., et al. Laryngeal transplantation and 40-month follow up. NEJM 344 (2001) 1676-1679
3. Potter C.P., and Birchall M.A. Laryngectomees' views of laryngeal transplantation. Transpl Int 11 (1998) 433-438
4. Brenner M.J., Tung T.H., Jensen J.N., et al. The spectrum of complications of immunosuppression: is the time right for hand transplantation?. J Bone Joint Surg Am 84 (2002) 1861-1870
5. Kinlen L.J. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 78 (1985) 44-49
6. Neuhas P., Klupp J., and Langrehr J.M. mTOR inhibitors: an overview. Liver Transpl 7 (2001) 473-484
7. Schuler W., Sedrani R., Cottens S., et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64 (1997) 36-42
8. Abraham R.T., and Wiederrecht G.J. Immunopharmacology of rapamycin. Annu Rev Immunol 14 (1996) 483-510
9. Mabuchi S., Altomare D.A., Cheung M., et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 13 (2007) 4261-4270
10. Fernandez A., Marcen R., Pascual J., et al. Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia. Transpl Proc 38 (2006) 2453-2455
11. Khariwala S.S., Kjaergaard J., Lorenz R., et al. Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII). Laryngoscope 116 (2006) 814-820
12. Dana Farber Cancer Institute. Cisplatin and everolimus in treating patients with advanced solid tumors or recurrent or metastatic head and neck cancer. http://www.dana-farber.org/can/clinical/View.aspx?doc=CDR0000525762&audience=0 Accessed January 1, 2009
13. Khariwala S.S., Knott P.D., Dan O., et al. Pulsed immunosuppression with everolimus and anti-alphabetaTCR: laryngeal allograft preservation at 6 months. Ann Otol Rhinol Laryngol 115 (2006) 74-80
14. Shipchandler T.Z., Lorenz R.R., Lee W.T., et al. Laryngeal transplantation in the setting of cancer: a rat model. Laryngoscope 118 (2008) 2166-2171
15. Lott D.G., Shipchandler T.Z., Dan O., et al. A new mouse laryngeal transplantation rejection grading system. Laryngoscope (2009 Oct 29) [Epub ahead of print]
16. Shipchandler T.Z., Lott D.G., Lorenz R.R., et al. New mouse model for studying laryngeal transplantation. Ann Otol Rhinol Laryngol 118 (2009) 465-468
17. Colombetti S., Benigni F., Basso V., et al. Clonal anergy is maintained independently of T cell proliferation. J Immunol 169 (2002) 6178-6186
18. Valmori D., Tosello V., Souleimanian N.E., et al. Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells. J Immunol 17 (2006) 944-949
19. Abe M., and Thomson A.W. Influence of immunosuppressive drugs on dendritic cells. Transpl Immunol 11 (2003) 357-365
20. Matsue H., Yang C., Matsue K., et al. Contrasting impacts of immunosuppressive agents (rapamycin, FK506, cyclosporin A, and dexamethasone) on bidirectional dendritic cell-T cell interaction during antigen presentation. J Immunol 169 (2002) 3555-3564